EA201792356A1 - Агонисты рецептора 5-htи их композиции и способы использования - Google Patents
Агонисты рецептора 5-htи их композиции и способы использованияInfo
- Publication number
- EA201792356A1 EA201792356A1 EA201792356A EA201792356A EA201792356A1 EA 201792356 A1 EA201792356 A1 EA 201792356A1 EA 201792356 A EA201792356 A EA 201792356A EA 201792356 A EA201792356 A EA 201792356A EA 201792356 A1 EA201792356 A1 EA 201792356A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- addiction
- tobacco
- nicotine
- disorders
- smoking
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
В настоящем описании в некоторых вариантах осуществления представлены соединения. Также в некоторых вариантах осуществления представлены способы контроля массы, индуцирования насыщения и снижения потребления пищи, а также предотвращения и лечения ожирения, индуцированного антипсихотиком увеличения массы, диабета II типа, синдрома Прадера-Вилли, табачной/никотиновой зависимости, лекарственной аддикции, алкогольной аддикции, патологической игры в азартные игры, синдрома недостатка вознаграждения и сексуальной аддикции, нарушений обсессивно-компульсивного спектра и нарушений контроля импульсов (включая грызение ногтей и онихофагию), нарушенй сна (включая бессонницу, архитектуру фрагментированного сна и нарушения медленноволнового сна), недержание мочи, психиатрических нарушений (включая шизофрению, нервную анорексию и нервную булимию), болезни Альцгеймера, нарушения половой функции, нарушения эректильной функции, эпилепсии, двигательных нарушений (включая паркинсонизм и индуцированное антипсихотиком двигательное нарушение), гипертензии, дислипидемии, заболевания неалкогольного ожирения печени, заболевания почек, связанного с ожирением, и апноэ во сне. Также в некоторых вариантах осуществления представлены композиции, которые содержат соединение в настоящем описании, необязательно в комбинации с дополнительным средством, и способы снижения частоты курения табака у индивидуума, пытающегося снизить частоту курения табак; содействия отказу или уменьшению использования табачного продукта у индивидуума, пытающегося прекратить или уменьшить использование табачного продукта; содействия отказу от курения и предотвращения связанного увеличения массы; контроля увеличения массы, связанного с отказом от курения индивидуумом, пытающимся прекратить курить табак; снижения увеличения массы, связанного с отказом от курения индивидуумом, пытающимся прекратить курить табак; лечения никотиновой зависимости, аддикции и/или абстинентного синдрома у индивидуума, пытающегося вылечить никотиновую зависимость, аддикцию и/или абстинентный синдром; или снижения вероятности рецидива использования никотина индивидуумом, пытающимся прекратить использование никотина, которые включают введение соединения в настоящем описании, необязательно в комбинации с дополнительным средством.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153082P | 2015-04-27 | 2015-04-27 | |
| PCT/US2016/029308 WO2016176177A1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201792356A1 true EA201792356A1 (ru) | 2018-05-31 |
| EA034446B1 EA034446B1 (ru) | 2020-02-10 |
Family
ID=55949111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792356A EA034446B1 (ru) | 2015-04-27 | 2016-04-26 | Агонисты рецептора 5-htи их композиции и способы использования |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10392390B2 (ru) |
| EP (1) | EP3288946B1 (ru) |
| JP (1) | JP6675688B2 (ru) |
| KR (1) | KR102275505B1 (ru) |
| CN (1) | CN107873030B (ru) |
| AU (1) | AU2016255009B2 (ru) |
| BR (1) | BR112017023088B1 (ru) |
| CA (1) | CA3002544C (ru) |
| DK (1) | DK3288946T3 (ru) |
| EA (1) | EA034446B1 (ru) |
| ES (1) | ES2757922T3 (ru) |
| HK (1) | HK1244005B (ru) |
| HR (1) | HRP20192044T1 (ru) |
| HU (1) | HUE047169T2 (ru) |
| IL (1) | IL255171A0 (ru) |
| MX (2) | MX2017013902A (ru) |
| PT (1) | PT3288946T (ru) |
| WO (1) | WO2016176177A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| MA52861A (fr) | 2018-01-30 | 2021-05-05 | Apnimed Inc Delaware | Méthodes et compositions pour le traitement de l'apnée du sommeil |
| BR112021015600A2 (pt) * | 2019-02-08 | 2021-10-05 | The Brigham And Women's Hospital, Inc. | Métodos e composições para tratamento da apneia do sono |
| EP3955918A1 (en) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| WO2023076533A1 (en) * | 2021-10-29 | 2023-05-04 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| CA3240578A1 (en) * | 2021-12-10 | 2023-06-15 | GATC Health Corp | Methods of treating ptsd and neurological disorders |
| US20230293546A1 (en) * | 2022-03-10 | 2023-09-21 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2023225773A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| WO2024118987A1 (en) * | 2022-12-02 | 2024-06-06 | Arena Pharmaceuticals, Inc. | Methods of treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| WO2002036596A2 (en) * | 2000-11-03 | 2002-05-10 | Wyeth | CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES |
| ES2230382T3 (es) | 2000-11-03 | 2005-05-01 | Wyeth | Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c. |
| CA2482195A1 (en) | 2002-04-12 | 2003-10-23 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-04-26 US US15/567,116 patent/US10392390B2/en active Active
- 2016-04-26 PT PT167213206T patent/PT3288946T/pt unknown
- 2016-04-26 JP JP2017555768A patent/JP6675688B2/ja active Active
- 2016-04-26 KR KR1020177033892A patent/KR102275505B1/ko active IP Right Grant
- 2016-04-26 BR BR112017023088-7A patent/BR112017023088B1/pt active IP Right Grant
- 2016-04-26 CA CA3002544A patent/CA3002544C/en active Active
- 2016-04-26 CN CN201680037275.XA patent/CN107873030B/zh active Active
- 2016-04-26 MX MX2017013902A patent/MX2017013902A/es active IP Right Grant
- 2016-04-26 AU AU2016255009A patent/AU2016255009B2/en active Active
- 2016-04-26 WO PCT/US2016/029308 patent/WO2016176177A1/en active Application Filing
- 2016-04-26 DK DK16721320T patent/DK3288946T3/da active
- 2016-04-26 EA EA201792356A patent/EA034446B1/ru not_active IP Right Cessation
- 2016-04-26 HU HUE16721320A patent/HUE047169T2/hu unknown
- 2016-04-26 EP EP16721320.6A patent/EP3288946B1/en active Active
- 2016-04-26 ES ES16721320T patent/ES2757922T3/es active Active
-
2017
- 2017-10-22 IL IL255171A patent/IL255171A0/en active IP Right Grant
- 2017-10-27 MX MX2020005898A patent/MX2020005898A/es unknown
-
2018
- 2018-03-13 HK HK18103485.6A patent/HK1244005B/zh unknown
-
2019
- 2019-11-12 HR HRP20192044TT patent/HRP20192044T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6675688B2 (ja) | 2020-04-01 |
| HRP20192044T1 (hr) | 2020-02-07 |
| WO2016176177A1 (en) | 2016-11-03 |
| BR112017023088A2 (pt) | 2018-07-10 |
| AU2016255009B2 (en) | 2020-10-08 |
| JP2018519251A (ja) | 2018-07-19 |
| HK1244005B (zh) | 2020-04-17 |
| BR112017023088B1 (pt) | 2023-10-03 |
| DK3288946T3 (da) | 2019-11-25 |
| CN107873030A (zh) | 2018-04-03 |
| KR20170140317A (ko) | 2017-12-20 |
| EP3288946A1 (en) | 2018-03-07 |
| AU2016255009A1 (en) | 2017-12-14 |
| IL255171A0 (en) | 2017-12-31 |
| ES2757922T3 (es) | 2020-04-30 |
| CA3002544A1 (en) | 2016-11-03 |
| MX2020005898A (es) | 2020-08-13 |
| EP3288946B1 (en) | 2019-08-21 |
| PT3288946T (pt) | 2019-11-27 |
| KR102275505B1 (ko) | 2021-07-08 |
| MX2017013902A (es) | 2018-03-16 |
| US20180186797A1 (en) | 2018-07-05 |
| HUE047169T2 (hu) | 2020-04-28 |
| CA3002544C (en) | 2024-03-05 |
| NZ737412A (en) | 2021-06-25 |
| US10392390B2 (en) | 2019-08-27 |
| EA034446B1 (ru) | 2020-02-10 |
| CN107873030B (zh) | 2021-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792356A1 (ru) | Агонисты рецептора 5-htи их композиции и способы использования | |
| NZ750469A (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| MX2018001380A (es) | Agonistas del receptor 5-ht2c y composiciones y metodos de uso. | |
| MX2021000310A (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de las enfermedades que dependen de la familia de dedo de zinc ikaros (ikzf2). | |
| WO2006071548A3 (en) | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases | |
| TW200833341A (en) | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | |
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| MX2009006345A (es) | Compuestos utiles como inhibidores de proteina cinasa. | |
| MX2009006690A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
| MX2009009592A (es) | Aminopiridinas utiles como inhibidores de proteinas cinasas. | |
| TW200736250A (en) | Aminopyrimidines useful as kinase inhibitors | |
| WO2005076998A3 (en) | Rnai therapeutics for treatment of eye neovascularization diseases | |
| MX2011008549A (es) | [1, 2, 4] triazolo [1 ,5 -a] piridinas como inhibidores de cinasa. | |
| HK1138572A1 (en) | Aminopyrimidines useful as inhibitors of protein kinases | |
| IN2012DN00446A (ru) | ||
| EA202090043A1 (ru) | Диазабициклические замещенные имидазопиримидины и их применение | |
| MX2009010037A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
| TW200612841A (en) | Method of preparing tea extract and tea flavor | |
| MX2009011811A (es) | Aminopirimidinas utiles como inhibidores de cinasa. | |
| WO2007089945A3 (en) | Treating diseases by targeting silt3 | |
| MX2009004771A (es) | Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa. | |
| WO2011084366A3 (en) | Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| MX2010013726A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |